An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved restorative prostate cancer vaccine, Provenge, is satisfactory and has few squad effects, a fresh study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy online. "Provenge was approved based on both cover and clinical data," said captain researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.

This refuge information shows that there are very little philosophy effects. The advantage of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer standpoint crap than chemotherapy, which is the only other treatment option for these patients stretch mark removal costs. In addition, Provenge has improved survival over chemotherapy.

The so so survival time for men given Provenge is 4,5 months, although some patients gnome their lives extended by two to three years. "This is a newly at one's disposal treatment, with very small side effects, compared to anything else that a mortals would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual conclave in San Francisco.

Data from four condition 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved supremacy of freshness and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do respond activities without any restrictions, the researchers noted.

In terms of haughtiness effects, the most prevalent were flu-like symptoms such as chills, fever and headache, which were seen in 3,5 percent of the men. Usually it took only a hour or two for the symptoms to resolve. More of consequence side effects, such as infusion reactions, diseased 3,5 percent of the patients. Cerebrovascular problems feigned 3,5 percent of those who received the vaccine and 2,6 percent of those who received placebo, Hall's crowd found.

Dr Nelson Neal Stone, a clinical professor of urology and emanation oncology at Mount Sinai School of Medicine in New York City, said that "the ancillary chattels are be fond of having the flu and they can be managed with aspirin". However, Stone aciculiform to one big drawback to Provenge: cost. "I've heard $30000, I've heard $90000. I have no suggestion what it's wealthy to cost. And who's going to pay for it?" he said.

Provenge is a salutary (not preventive) vaccine that is made from the patient's own anaemic blood cells. Once removed from the patient, the cells are treated with the knock out and placed back into the patient. These treated cells then cause an unaffected response, which in turn kills cancer cells, while leaving conventional cells unharmed. According to the FDA, Provenge is given intravenously in a three-dose programme delivered in two-week intervals.

The vaccine was developed by Seattle-based Dendreon Corp, which conducted inaugural studies middle men with advanced prostate cancer who had already failed accepted hormone treatment. According to American Cancer Society estimates, more than 192000 supplemental cases of prostate cancer are diagnosed in the United States each year, and 27360 men Euphemistic depart from the disease.

Prostate cancer is the most bourgeois form of cancer diagnosed in American men, after rind cancer. More than 2 million American men who have had prostate cancer at some juncture are still thronging today provillus shop. The death rate is going down and the disease is being found earlier, according to the cancer society.